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1455appropriate. The Student t-test or Mann-Whitney U test was used
for the comparison of continuous variables, as appropriate. Data
have been analyzed according to the intention-to-treat principle.
Two-sided tests were used, and a p value <0.025 (using the
Bonferroni adjustment, alpha level/number of comparison: 0.05/2)
was the statistical signiﬁcance level. MACE curves using the
Kaplan-Meier methods were produced for treatment group and
compared by the log-rank test. The software SPSS version 17.0
(SPSS Italia, Florence, Italy) was used for all statistical analyses.
One-year FU was complete in all but 5 of 240 patients (2 pa-
tients in the adenosine group, 1 patient in the nitroprusside group,
and 2 patients in the placebo group). As in the main study, de-
mographics, cardiovascular risk factors, ischemic times, Killip
classes and discharge therapy did not differ signiﬁcantly among
treatment groups (p ¼ NS, data not shown). Of note, compliance
with therapy at FU was nearly 90% for all drugs and was similar
among treatment groups (p ¼ NS). Baseline end-diastolic and end-
systolic left ventricular volumes were similar between adenosine-
treated patients (105  19 ml and 62  15 ml, respectively) or
nitroprusside-treated patients (107  21 ml and 64  16 ml,
respectively) and saline-treated patients (104  20 ml and 65  15
ml, respectively), p ¼ 0.59, p ¼ 0.42, p ¼ 0.48, p ¼ 0.68,
respectively), with no signiﬁcant differences between adenosine-
and nitroprusside-treated patients (p ¼ 0.57 and p ¼ 0.61,
respectively). However, at 1-year echocardiographic FU, the left
ventricular remodeling rate occurred less frequently in the
adenosine-treated patients as compared with the placebo-treated
patients (6% vs. 23%, p ¼ 0.006), whereas it was similar between
nitroprusside- and placebo-treated patients (18% vs. 23%,
p ¼ 0.43), and tended to be less frequent in the adenosine-treated
patients as compared with the nitroprusside-treated patients
(p ¼ 0.07). The MACE rate at 1-year FU was signiﬁcantly lower
in the adenosine group (2 deaths, 1 myocardial infarction, 6 target-
lesion revascularizations, 1 heart failure) as compared with the
placebo group (4 deaths, 5 myocardial infarctions, 7 target-lesion
revascularizations, 7 heart failures) (13% vs. 31%, p ¼ 0.01),
whereas it was similar between the nitroprusside (3 deaths, 4
myocardial infarctions, 7 target–lesion revascularizations, 3 heart
failures) and the placebo groups (21% vs. 31%, p ¼ 0.21) and
between the adenosine and the nitroprusside groups (p ¼ 0.21). Of
note, hospitalization for heart failure tended to occur less frequently
in the adenosine group as compared with the placebo group (1% vs.
9%, p ¼ 0.06). Kaplan-Meier curves for MACE-free survival ac-
cording to treatment allocation are shown in Figure 1.
In this study, we showed that high-dose intracoronary adenosine
administration in patients with STEMI undergoing primary PCI is
associated with improved clinical outcomes after 1 year, mainly because
of a reduction in hospitalization for heart failure and less left ventricular
negative remodeling (with a statistical power of 99% for adenosine vs.
saline and 95% for nitroprusside vs. saline). Because this effect was
borderline after 1 month (2), it suggests that the beneﬁcial effects of
adenosine on clinical outcomes need more time in order to be
demonstrated, as adenosine may have an impact on the rate of left
ventricular remodeling (4) after STEMI. The adenosine-related im-
provements of left ventricular remodeling and clinical outcome are
probably due to its effects on MVO and infarct size. Indeed, both re-
ductions ofMVOand infarct size have been related to improved clinical
outcome (1). Multiple cardioprotective effects of adenosine have been
reported, including its potent direct vasodilatory effect on the coronary
microcirculation, its anti-inﬂammatory properties against neutrophils,
and its ability to inhibit platelet aggregation, to stimulate angiogenesis,and to mimic ischemic pre-conditioning, thus probably accounting for
the beneﬁcial effects observed in this trial (5). In particular, on the basis
of these effects, left ventricular remodeling improvementmay be related
to a better healing process of a smaller infarct area in adenosine-treated
patients (suggested also by the smaller enzymatic infarct size observed in
the main study for adenosine-treated patients). This study is not pow-
ered, however, to demonstrate a mortality beneﬁt, thus further studies
should test larger populations for the impact of intracoronary adenosine
after thrombus aspiration in STEMI on survival.*Giampaolo Niccoli, MD, PhD
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Cardiac Arrest in
Minnesota High School
Student Athletes
The Limitations of
Catastrophic Insurance ClaimsTo the Editor: An accurate understanding of the incidence of car-
diovascular events in athletes is central to the development and
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1456evaluation of screening guidelines. A recent study by Roberts and
Stovitz (1) reported a remarkably low rate of sudden cardiac death
(SCD) in Minnesota high school athletes on the basis of analysis of
catastrophic insurance claims. The low rate of SCD was linked to a
statewide pre-participation screening process involving a standard-
ized history and physical examination conducted every 3 years (1).
However, critical examination of the study methodology raises
important concerns about the validity of the study ﬁndings and
conclusions. This letter draws attention to major ﬂaws and presents
an alternative incidence of sudden cardiac arrest (SCA) inMinnesota
high school athletes on the basis of a search of public media reports.
The authors searched catastrophic insurance claims over a
19-year period (1993 to 2012) to identify cases of SCD during high
school athletic practices and games. The reported incidence of
SCD in Minnesota high school athletes was 0.24 per 100,000
athlete-years over 19 years and 0.11 per 100,000 athlete-years over
the last decade (1). The methodology is analogous to a widely cited
1998 study that reported an incidence of SCD in Minnesota high
school athletes of 0.46 per 100,000 athlete-years (2). The study
does not include cases resulting in death outside of an ofﬁcial high
school–sponsored sporting event such as unofﬁcial training sessions
or participation with club/select teams. The report brieﬂy mentions
cases of SCA in which the persons were saved but implies they were
not athletes or at least the cases did not happen during school-
sponsored events.
The authors associate a standardized pre-participation evaluation
with the low rate of SCD, a conclusion further promoted by a
corresponding editorial (3). However, the study provides no data as
to the results of the screening evaluations performed or the cardiac
conditions identiﬁed. If the rate of cardiovascular events in Min-
nesota high school athletes is truly as low as reported, one possible
conclusion is that no cardiovascular screening of any type is actually
needed.
We conducted a review of public media reports by searching the
Parent Heart Watch database over the last 10 years of the study
period in which the authors report only a single case of SCD. The
Parent Heart Watch database tracks cases of SCA through sys-
tematic Internet search protocols. Each case was reviewed to assess
the circumstances of the event and conﬁrm participation on a
Minnesota high school athletic team.
Between 2003 and 2012, public media reports identiﬁed 13 cases
of SCA in Minnesota high school athletes (all in males), including
6 cases of SCD and 7 cases of SCA in student athletes who sur-
vived. Roberts and Stovitz (1) document 917,069 unduplicated
high school athletes in Minnesota from 2003 to 2012. Thus, the
incidence of all SCA in Minnesota high school athletes is 1.4 per
100,000 athlete-years, and the incidence of SCD 0.65 per 100,000
athlete-years. Of the 6 deaths documented in media reports, only
1 would have been eligible for death beneﬁts from an insurance
claim, yet 4 of 6 deaths occurred during sports participation. An
alarming 46% of cases (6 of 13) occurred in boys’ basketball. The
incidence of SCA in Minnesota high school boys’ basketball is
w4.7 per 100,000 athlete-years.
Search of catastrophic insurance claims is not an accuratemethod to
conduct death surveillance in athletes. The Minnesota pre-
participation evaluation did not prevent at minimum 13 cases of
SCA between 2003 and 2012. There remains no evidence that a
screening program on the basis of history and physical examina-
tion alone is effective in identifying athletes with at-risk conditions or
in preventing SCA. Reports examining only death rates will under-
estimate the incidence of life-threatening cardiovascular events andfalsely assume that current screening strategies are effective. To sug-
gest that catastrophic insurance claims are a reliable measure of inci-
dence in support of current screening strategies is unsubstantiated.
Although many questions and challenges to more intensive cardio-
vascular screening in athletes exist, we must recognize that scientiﬁc
limitations andmisinterpretations have perpetuated an underestimate
of SCA in athletes and perhaps impeded progress toward the evalu-
ation and implementation of more effective preventive programs.*Jonathan A. Drezner, MDy
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Patients With Nonvalvular
Atrial Fibrillation
Violi et al. (1) are to be commended for their large study on the
prevalence of subclinical peripheral artery disease (PAD) among
patients with nonvalvular atrial ﬁbrillation. Indeed, the ankle-
brachial index (ABI) enables the detection of a substantial subset
of individuals with asymptomatic (or with atypical symptoms of)
PAD in diverse populations, and beyond its diagnostic interest, a
low ABI is predictive for stroke, as highlighted recently in a meta-
analysis (2). Violi et al. (1) reported an even higher than expected
21% prevalence of PAD detected by an ABI 0.90, almost
doubling the proportion of patients with “vascular disease” as
deﬁned in the CHADS2-VASc (congestive heart failure [or left
ventricular systolic dysfunction]; hypertension [blood pressure
consistently >140/90 mm Hg or on hypertension medication];
age 75 years; diabetes mellitus; previous stroke, transient ischemic
attack, or thromboembolism; vascular disease [e.g., peripheral artery
disease, myocardial infarction, aortic plaque]; age 65 to 74 years; sex
